US20100168254A1 - Hydrogel composition for the treatment of dermatological disorders - Google Patents

Hydrogel composition for the treatment of dermatological disorders Download PDF

Info

Publication number
US20100168254A1
US20100168254A1 US12/644,494 US64449409A US2010168254A1 US 20100168254 A1 US20100168254 A1 US 20100168254A1 US 64449409 A US64449409 A US 64449409A US 2010168254 A1 US2010168254 A1 US 2010168254A1
Authority
US
United States
Prior art keywords
hydrogel
dermatitis
treatment
acne
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/644,494
Inventor
Hartwig Steckel
Karin Hoffmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intendis GmbH
Original Assignee
Intendis GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intendis GmbH filed Critical Intendis GmbH
Priority to US12/644,494 priority Critical patent/US20100168254A1/en
Assigned to INTENDIS GMBH reassignment INTENDIS GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: STECKEL, HARTWIG, HOFFMANN, KARIN
Publication of US20100168254A1 publication Critical patent/US20100168254A1/en
Priority to US14/541,784 priority patent/US9731021B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Definitions

  • Perioral dermatitis is a dermatological disorder of unclear origin.
  • the patients suffer from red papules that typically effects the perioral area, nasolbial folds or perioccular area (Hafeez: Int J. Dermatol. 2003, 42(7):514) sometimes accompanied by mild peeling. Itching or burning are reported from patients. Females are more likely to be affected.
  • Perioral dermatitis may also be treated following the “Null” therapy, i.e. to do anything about the dermatitis and wait until improvement.
  • This “Null” therapy is often not acceptable from a patient's perspective as the signs of the perioral dermatitis are cosmetically in-elegant and might affect the patients mind.
  • Hydrogels are commonly known as a carrier for active drug substances for the topical delivery of drugs for the treatment of e.g. acne, rosacea, burns or pruritus. As such, hydrogels offer a cooling effect to the skin, thereby supporting the therapeutic action of the incorporated active drug substance.
  • hydrogel formulations including an active drug substance are, for instance, disclosed in US 2003/119783 describing an aqueous vehicle containing metronidazole in a gel for the treatment of rosacea.
  • U.S. Pat. No. 5,955,109 describes an aqueous gelated vehicle containing the active drug substance tretinoin bound to polymer particles for the treatment of acne.
  • hydrogels are provided in WO 99/25332, US 2005/026982, WO 2007/082780. However, all of these formulations contain at least one active drug substance (pharmaceutically active ingredient) which are not in the scope of the present invention.
  • hydrogel composition as described within this application which does not contain any active drug substance is useful in treating dermatological disorders, especially perioral dermatitis.
  • the object of the present invention is therefore the use of a hydrogel composition which is essentially free of active drug compounds for the manufacture of a product for the treatment of perioral dermatitis.
  • active drug compound or “pharmaceutically active ingredient” refers to compounds with proved pharmaceutical activity demonstrated in clinical trials and approved as a drug by the European Medicines Agency (EMEA) or the US Food and Drug Administration (FDA).
  • EMEA European Medicines Agency
  • FDA US Food and Drug Administration
  • essentially free of active drug compound” or “essentially free of pharmaceutically active ingredients” means that no “active drug compound” or “pharmaceutically active ingredient” has been intended to be added to the composition.
  • the total amount of pharmaceutically active ingredients as a result of unintended contamination is therefore well below 0.05%, preferably below 0.01%.
  • Most preferred is a composition in which no amount of any active drug compound (pharmaceutical ingredient) can be detected with standard analytical methods used in pharmaceutical technology.
  • the hydrogel composition according to the invention is preferably based on a mixture of propylene glycol, polyacrylic acid, medium-chain triglycerides and lecithine as described in the examples section. Various further ingredients may be added.
  • Benzoic acid is preferably added as a preservative. It is important to know that benzoic acid alone applied in the amounts described below does not provide any effect in the treatment of perioral dermatitis or other dermatological disorder. Benzoic acid is therefore not considered to be an active drug compound according to this invention.
  • a composition in form of a hydrogel which is essentially free of active pharmaceuticals is therefore an object of the invention. More specifically an object of the invention is a composition in form of a hydrogel which is essentially free of active pharmaceuticals, wherein the hydrogel contains at least a surfactant, propylene glycol, lecithin and a lipid.
  • a preferred embodiment of the invention is a composition in form of a hydrogel which is essentially free of active pharmaceuticals according to claim 1 , wherein the hydrogel contains
  • Example 1 The most preferred embodiments of the invention are provided in Example 1.
  • the hydrogel is manufactured according to prior art methods, such as in U.S. Pat. No. 6,534,070.
  • composition according to the invention does show (in addition to its effect in perioral dermatitis as described herein) beneficial effects in the treatment of various kinds of dermatological disorders, such as acne (e.g. Acne vulgaris) and seborrhoic dermatitis.

Abstract

The present patent application is related to a hydrogel composition which is essentially free of active drugs for the manufacture of a product for the treatment of dermatological disorders, especially perioral dermatitis, acne or seborrheic dermatitis.

Description

  • This application claims the priority according to the Paris Convention of the European Patent application EP 08075966.5 (filing date: Dec. 23, 2008) as well as all benefits from earlier U.S. application Ser. No. 61/140,107 (filing date: Dec. 23, 2008), which are both incorporated herein by reference.
    • BACKGROUND OF THE INVENTION
  • Perioral dermatitis is a dermatological disorder of unclear origin. The patients suffer from red papules that typically effects the perioral area, nasolbial folds or perioccular area (Hafeez: Int J. Dermatol. 2003, 42(7):514) sometimes accompanied by mild peeling. Itching or burning are reported from patients. Females are more likely to be affected.
  • A number of treatments have been suggested including oral antibiotics (e.g. tetracycline), topical antibiotics (such as metronidazole), immunomodulating agents (such as Pimecrolimus) and corticosteroids (such as mometasone furoate). However, these treatments have been criticised for their side-effects (Hengge: J Am Acad Dermatol. 2006, 54(1): 1-15).
  • Perioral dermatitis may also be treated following the “Null” therapy, i.e. to do anything about the dermatitis and wait until improvement. This “Null” therapy is often not acceptable from a patient's perspective as the signs of the perioral dermatitis are cosmetically in-elegant and might affect the patients mind.
  • Hydrogels are commonly known as a carrier for active drug substances for the topical delivery of drugs for the treatment of e.g. acne, rosacea, burns or pruritus. As such, hydrogels offer a cooling effect to the skin, thereby supporting the therapeutic action of the incorporated active drug substance.
  • Examples of such hydrogel formulations including an active drug substance are, for instance, disclosed in US 2003/119783 describing an aqueous vehicle containing metronidazole in a gel for the treatment of rosacea.
  • U.S. Pat. No. 5,955,109 describes an aqueous gelated vehicle containing the active drug substance tretinoin bound to polymer particles for the treatment of acne.
  • Further embodiments of hydrogels are provided in WO 99/25332, US 2005/026982, WO 2007/082780. However, all of these formulations contain at least one active drug substance (pharmaceutically active ingredient) which are not in the scope of the present invention.
  • Surprisingly, we have now found that a hydrogel composition as described within this application which does not contain any active drug substance is useful in treating dermatological disorders, especially perioral dermatitis.
  • The object of the present invention is therefore the use of a hydrogel composition which is essentially free of active drug compounds for the manufacture of a product for the treatment of perioral dermatitis.
  • The term “active drug compound” or “pharmaceutically active ingredient” refers to compounds with proved pharmaceutical activity demonstrated in clinical trials and approved as a drug by the European Medicines Agency (EMEA) or the US Food and Drug Administration (FDA). The term “essentially free of active drug compound” or “essentially free of pharmaceutically active ingredients” means that no “active drug compound” or “pharmaceutically active ingredient” has been intended to be added to the composition. The total amount of pharmaceutically active ingredients as a result of unintended contamination is therefore well below 0.05%, preferably below 0.01%. Most preferred is a composition in which no amount of any active drug compound (pharmaceutical ingredient) can be detected with standard analytical methods used in pharmaceutical technology.
  • The hydrogel composition according to the invention is preferably based on a mixture of propylene glycol, polyacrylic acid, medium-chain triglycerides and lecithine as described in the examples section. Various further ingredients may be added. Benzoic acid is preferably added as a preservative. It is important to know that benzoic acid alone applied in the amounts described below does not provide any effect in the treatment of perioral dermatitis or other dermatological disorder. Benzoic acid is therefore not considered to be an active drug compound according to this invention.
  • A composition in form of a hydrogel which is essentially free of active pharmaceuticals is therefore an object of the invention. More specifically an object of the invention is a composition in form of a hydrogel which is essentially free of active pharmaceuticals, wherein the hydrogel contains at least a surfactant, propylene glycol, lecithin and a lipid. A preferred embodiment of the invention is a composition in form of a hydrogel which is essentially free of active pharmaceuticals according to claim 1, wherein the hydrogel contains
  • (i) 5-15% propylene glycol
    (ii) 0-2% polyacrylic acid
    (iii) 0.5-3% lecithin
    (iv) 0.5-3% medium chain triglycerides or macrogol-glycerol hydroxystearate.
  • The most preferred embodiments of the invention are provided in Example 1.
  • The hydrogel is manufactured according to prior art methods, such as in U.S. Pat. No. 6,534,070.
  • Surprisingly, the composition according to the invention does show (in addition to its effect in perioral dermatitis as described herein) beneficial effects in the treatment of various kinds of dermatological disorders, such as acne (e.g. Acne vulgaris) and seborrhoic dermatitis.
  • It is therefore a further object of the invention to provide a method of treatment for humans suffering from dermatological disorders, such as perioral dermatitis, seborrhoic dermatitis or acne, by topical administration of a hydrogel as described in this document.
    • EXAMPLES
  • 1.) Examples for hydrogels to be used in the indication perioral dermatitis or in the indication, seborrhoic dermatitis':
  • 1 2 3 4 5 6 7 8 9
    Benzoic acid 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
    Sodium edentate 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
    Sodium hydroxide 0.2 0.1 0.2 2   — 0.1 0.1 0.2 0.2
    Polyacrylic acid 1.0 — 1.0 1.0 — 0.5 — 1.0 —
    Acrylic acid copolymer — 0.5 — — — — 0.3 — —
    Hydroxyethylcellulose — — — — — — — — 0.5
    Xanthan gum — — — — 0.8 0.5 0.3 — —
    Propylene glycol 12.0  8.0 12.0  6.0 12.0  12.0  12.0  8.0 8.0
    Glycerol — — — 6.0 — — — 8.0 —
    Polysorbate 80 1.5 1.5 1.5 — 1.5 1.5 1.5 1.5 1.5
    Macrogol-glycerol- — — 1.5 — — — — —
    hydroxystearate
    Medium chain 1.0 2.0 1.0 1.0 1.0 3.0 3.0 1.0 1.0
    triglycerides
    Dimeticone — — 1.0 — — — — — —
    Liquid paraffin — — — — 1.0 — — — —
    Lecithin 1.0 2.0 1.0 1.0 1.0 1.5 1.0 1.0 1.0
    Purified water to 100.0  100.0  100.0  100.0  100.0  100.0  100.0  100.0  100.0 

    Data provided in weight percent (wt. %).
    2) In a recent observational study, 16 patients suffering from perioral dermatitis were treated with an active-free (=free of any active pharmaceutical ingredient) hydrogel formulation. Surprisingly, we observed a significant improvement of overall lesion count, perioral dermatitis (POD) score and investigators global assessment (IGA) score (FIG. 1-3).
    3.) Patients suffering from Acne vulgaris are treated twice daily with one of the compositions according to Example 1. Surprisingly after 6 weeks the majority of the patients show a clinically remarkably improvement of their skin disorder.
    4.) Patients suffering from seborrheic dermatitis are treated twice daily with one of the compositions according to Example 1. Surprisingly after 6 weeks the majority of the patients show a clinically remarkably improvement of their dermatological disease.
  • Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The preceding preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.
  • The entire disclosures of all applications, patents and publications, cited herein and of corresponding European application No. 08075966.5, filed Dec. 23, 2008, are incorporated by reference herein.
  • From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention and, without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

Claims (11)

1. A composition in form of a hydrogel which is essentially free of active pharmaceuticals.
2. A composition in form of a hydrogel which is essentially free of active pharmaceuticals according to claim 1, wherein the hydrogel contains at least a surfactant, propylene glycol, lecithin and a lipid.
3. A composition in form of a hydrogel which is essentially free of active pharmaceuticals according to claim 1, wherein the hydrogel contains
(i) 5-15% propylene glycol
(ii) 0-2% polyacrylic acid
(iii) 0.5-3% lecithin
(iv) 0.5-3% medium chain triglycerides or macrogol-glycerol hydroxystearate.
4. A composition in form of a hydrogel which is essentially free of active pharmaceuticals according to claim 1, wherein the hydrogel is consisting of one of the following compositions:
1 2 3 4 5 6 7 8 9 Benzoic acid 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 Sodium edentate 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 Sodium hydroxide 0.2 0.1 0.2 2   — 0.1 0.1 0.2 0.2 Polyacrylic acid 1.0 — 1.0 1.0 — 0.5 — 1.0 — Acrylic acid — 0.5 — — — — 0.3 — — copolymer Hydroxyethylcellulose — — — — — — — — 0.5 Xanthan gum — — — — 0.8 0.5 0.3 — — Propylene glycol 12.0  8.0 12.0  6.0 12.0  12.0  12.0  8.0 8.0 Glycerol — — — 6.0 — — — 8.0 — Polysorbate 80 1.5 1.5 1.5 — 1.5 1.5 1.5 1.5 1.5 Macrogol-glycerol- — — 1.5 — — — — — hydroxystearate Medium chain 1.0 2.0 1.0 1.0 1.0 3.0 3.0 1.0 1.0 triglycerides Dimeticone — — 1.0 — — — — — — Liquid paraffin — — — — 1.0 — — — — Lecithin 1.0 2.0 1.0 1.0 1.0 1.5 1.0 1.0 1.0 Purified water to 100.0  100.0  100.0  100.0  100.0  100.0  100.0  100.0  100.0 
5. A method for the treatment of dermatological disorders, especially perioral dermatitis, acne or seborrheic dermatitis, comprising administering a hydrogel which is essentially free of active pharmaceuticals.
6. A method according to claim 5, wherein the hydrogel contains at least a surfactant, propylene glycol, lecithin and a lipid.
7. A method for the treatment of perioral dermatitis, acne or seborrheic dermatitis according to claim 5, wherein the hydrogel contains
(i) 5-15% propylene glycol
(ii) 0-2% polyacrylic acid
(iii) 0.5-3% lecithin
(iv) 0.5-3% medium chain triglycerides or macrogol-glycerol hydroxystearate.
8. A method for the treatment of perioral dermatitis, acne or seborrheic dermatitis comprising administering the composition of claim 4.
1 2 3 4 5 6 7 8 9 Benzoic acid 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 Sodium edentate 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 Sodium hydroxide 0.2 0.1 0.2 2   — 0.1 0.1 0.2 0.2 Polyacrylic acid 1.0 — 1.0 1.0 — 0.5 — 1.0 — Acrylic acid — 0.5 — — — — 0.3 — — copolymer Hydroxyethylcellulose — — — — — — — — 0.5 Xanthan gum — — — — 0.8 0.5 0.3 — — Propylene glycol 12.0  8.0 12.0  6.0 12.0  12.0  12.0  8.0 8.0 Glycerol — — — 6.0 — — — 8.0 — Polysorbate 80 1.5 1.5 1.5 — 1.5 1.5 1.5 1.5 1.5 Macrogol-glycerol- — — 1.5 — — — — — hydroxystearate Medium chain 1.0 2.0 1.0 1.0 1.0 3.0 3.0 1.0 1.0 triglycerides Dimeticone — — 1.0 — — — — — — Liquid paraffin — — — — 1.0 — — — — Lecithin 1.0 2.0 1.0 1.0 1.0 1.5 1.0 1.0 1.0 Purified water to 100.0  100.0  100.0  100.0  100.0  100.0  100.0  100.0  100.0 
9. A method of treatment for humans suffering from dermatological disorders, such as perioral dermatitis, seborrhoic dermatitis or acne, by topical administration of a hydrogel composition according to claim 1.
10. A method of claim 6 for the treatment of perioral dermatitis, acne or seborrheic dermatitis.
11. A method of claim 7 for the treatment of perioral dermatitis, acne or seborrheic dermatitis.
US12/644,494 2008-12-23 2009-12-22 Hydrogel composition for the treatment of dermatological disorders Abandoned US20100168254A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/644,494 US20100168254A1 (en) 2008-12-23 2009-12-22 Hydrogel composition for the treatment of dermatological disorders
US14/541,784 US9731021B2 (en) 2008-12-23 2014-11-14 Hydrogel composition for the treatment of dermatological disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14010708P 2008-12-23 2008-12-23
EP08075966.5 2008-12-23
EP08075966A EP2201930A1 (en) 2008-12-23 2008-12-23 Hydrogel composition for the treatment of dermatological disorders
US12/644,494 US20100168254A1 (en) 2008-12-23 2009-12-22 Hydrogel composition for the treatment of dermatological disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/541,784 Continuation US9731021B2 (en) 2008-12-23 2014-11-14 Hydrogel composition for the treatment of dermatological disorders

Publications (1)

Publication Number Publication Date
US20100168254A1 true US20100168254A1 (en) 2010-07-01

Family

ID=40647157

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/644,494 Abandoned US20100168254A1 (en) 2008-12-23 2009-12-22 Hydrogel composition for the treatment of dermatological disorders
US14/541,784 Active 2030-04-18 US9731021B2 (en) 2008-12-23 2014-11-14 Hydrogel composition for the treatment of dermatological disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/541,784 Active 2030-04-18 US9731021B2 (en) 2008-12-23 2014-11-14 Hydrogel composition for the treatment of dermatological disorders

Country Status (6)

Country Link
US (2) US20100168254A1 (en)
EP (2) EP2201930A1 (en)
AR (1) AR074840A1 (en)
ES (1) ES2739658T3 (en)
TW (1) TW201028177A (en)
WO (1) WO2010072421A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013521300A (en) * 2010-03-03 2013-06-10 ネオキュティス エスアー Compositions and methods for the treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5888540A (en) * 1993-10-29 1999-03-30 Sugden; Keith Pharmaceutical products
WO1999025332A1 (en) * 1997-11-19 1999-05-27 Schering Aktiengesellschaft Composition with azelaic acid
US5955109A (en) * 1985-12-18 1999-09-21 Advanced Polymer Systems, Inc. Methods and compositions for topical delivery of retinoic acid
US6211296B1 (en) * 1998-11-05 2001-04-03 The B. F. Goodrich Company Hydrogels containing substances
US20030119783A1 (en) * 2001-12-24 2003-06-26 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole
US20050026982A1 (en) * 2003-06-10 2005-02-03 Soenke Johannsen Composition that consists of alkanedicarboxylic acids and a pharmaceutical active ingredient

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1588697A1 (en) * 2004-04-16 2005-10-26 Kurt H. Prof. Dr. Bauer Emulsion gel for topical application of pharmaceuticals
JP2008520735A (en) * 2004-11-22 2008-06-19 ニュー‐ティーン カンパニー，インク． Topical skin patch
DE102006004804A1 (en) * 2006-01-23 2007-07-26 Intendis Gmbh Use of alpha, omega-N-alkanedicarboxylic acid and retinoid for producing rosacea treatment preparation

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955109A (en) * 1985-12-18 1999-09-21 Advanced Polymer Systems, Inc. Methods and compositions for topical delivery of retinoic acid
US5888540A (en) * 1993-10-29 1999-03-30 Sugden; Keith Pharmaceutical products
WO1999025332A1 (en) * 1997-11-19 1999-05-27 Schering Aktiengesellschaft Composition with azelaic acid
US6534070B1 (en) * 1997-11-19 2003-03-18 Schering Aktiengesellschaft Composition with azelaic acid
US6211296B1 (en) * 1998-11-05 2001-04-03 The B. F. Goodrich Company Hydrogels containing substances
US20030119783A1 (en) * 2001-12-24 2003-06-26 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole
US20050026982A1 (en) * 2003-06-10 2005-02-03 Soenke Johannsen Composition that consists of alkanedicarboxylic acids and a pharmaceutical active ingredient

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Hoffman, Hydrogels for biomedical applications, Ann N Y Acad Sci. 2001 Nov; 944:62-73 *
VERSENETM Na Disodium EDTA Chelating Agent, October 2009, available at http://msdssearch.dow.com/PublishedLiteratureDOWCOM/dh_0421/0901b80380421c33.pdf?filepath=versene/pdfs/noreg/113-01340.pdf&fromPage=GetDoc *

Also Published As

Publication number Publication date
EP2201930A1 (en) 2010-06-30
ES2739658T3 (en) 2020-02-03
US20150182630A1 (en) 2015-07-02
TW201028177A (en) 2010-08-01
WO2010072421A2 (en) 2010-07-01
US9731021B2 (en) 2017-08-15
AR074840A1 (en) 2011-02-16
WO2010072421A3 (en) 2010-08-19
EP2381916B1 (en) 2019-05-08
EP2381916A2 (en) 2011-11-02

Similar Documents

Publication Publication Date Title
RU2467759C2 (en) Composition for local use and its applications
US6238683B1 (en) Anhydrous topical skin preparations
WO2018107130A1 (en) Composition for treating wounds and other dermatological conditions
US20210169902A1 (en) Use of oxygenated cholesterol sulfates (ocs) to treat inflammatory skin disease and skin lesions
US8232276B2 (en) Anhydrous topical skin preparations
JP2021119208A (en) Strontium based compositions and formulations for pain, pruritus and inflammation
US20070128287A1 (en) Dermal composition for external use
JP2015530380A (en) Composition for treating psoriasis
US8673356B2 (en) Stable fixed dose topical formulation
US9731021B2 (en) Hydrogel composition for the treatment of dermatological disorders
WO2022217147A1 (en) Methods for improving cutaneous permeation of cannabinoids and fatty acid amides
US20230037905A1 (en) Topical composition comprising tofacitinib and fingolimod
US20230320984A1 (en) Tofacitinib-containing anhydrous elastomer-based gel formulations
US20220305076A1 (en) Topical cyclosporine for treating psoriasis and other ailments
JP2018193329A (en) Transglutaminase expression promoter
JP2017088558A (en) Ceramide synthesis enhancer
JP2017088559A (en) Filaggrin production enhancer
JP7214331B2 (en) Pharmaceutical composition
US20190021995A1 (en) Formulation for treatment of peripheral joints, spinal joints and/or extracellular matrix elements of connective tissue, method of manufacture and uses
WO2023168004A1 (en) Topical formulation to decrease skin inflammation or redness
CN114828840A (en) Improved topical compositions of colchicine
JP2019006697A (en) Active oxygen scavenger
JP2019006696A (en) Active oxygen scavenger

Legal Events

Date Code Title Description
AS Assignment

Owner name: INTENDIS GMBH,GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:STECKEL, HARTWIG;HOFFMANN, KARIN;SIGNING DATES FROM 20100121 TO 20100128;REEL/FRAME:023983/0201

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION